Metformin Hydrochloride API Market: Introduction
According to the report, the global metformin hydrochloride API market was valued at
~US$ 300 Mn in 2020 and is projected to
expand at a CAGR of ~5% from 2021 to 2031.
Metformin hydrochloride is primarily used in the treatment of diabetes. The
prevalence of diabetes is expected to increase across the world due to change
in lifestyle and factors such as malnutrition and genetic mutations. According
to government and private organizations operating in the diabetes industry,
diabetes is considered one of the top fatal diseases globally. According to the
American Diabetes Association, diabetes accounts for around 71,000 deaths in
the U.S. each year. Diabetes is more prevalent in the geriatric population.
According to the American Diabetes Association, over 25% of the
diabetic patients in the U.S. are aged 65 years and above.
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=82470
North America held a major share of the global metformin hydrochloride
API market in 2020 due to high procurement of metformin
hydrochloride API by pharmaceutical companies and contract manufacturing
organizations in the region. The metformin hydrochloride API market in Asia
Pacific is expected to expand at a high CAGR of 6.9% from 2021 to 2031.
Rise in Prevalence of Diabetes to Drive Market
The rise in prevalence of diabetes is projected to drive the global
metformin hydrochloride API market during the forecast period. Diabetes is a
critical long-term condition with a major impact on the lives and well-being of
individuals across the world. It is among the top 10 causes of death in adults,
and was estimated to have caused 4.2 million deaths globally
in 2019. According to the International Diabetes Federation, the
global prevalence of diabetes was 9.3% (463 million people)
in 2019 and expected to reach 10.2% (578
million people) by 2030 and 10.9% (700
million people) by 2045.
Request COVID Analysis on Metformin
Hydrochloride API Market –
https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=82470
High income countries have higher prevalence of diabetes i.e., 10.4% compared
to low-income countries at 4.0%. Around 374 million
people are at increased risk of developing type 2 diabetes.
Metformin Hydrochloride to Dominate Global Market
In terms of product, the global metformin hydrochloride API market has
been classified into metformin hydrochloride, metformin hydrochloride DC, and
others. The metformin hydrochloride segment dominated the global metformin
hydrochloride API market in 2020, and the trend is anticipated to
continue during the forecast period. The segment is likely to dominate the
market due to high consumption of metformin hydrochloride by pharmaceutical
companies and availability of products in the market.
Pharmaceutical Companies Held Major Share of
Metformin Hydrochloride API Market
Based on end user, the global metformin hydrochloride API market has
been categorized into pharmaceutical companies, contract research
organizations, and others. The pharmaceutical companies segment held a major
share of the global metformin hydrochloride API market in 2020. The
pharmaceutical companies dominance can be attributed to increase in production
of metformin hydrochloride drugs, rise in R&D, and presence of a large
number of pharmaceutical companies.
Extended Release Tablet to be Preferred
In terms of dosage form, the global metformin hydrochloride API market
has been divided into tablet, extended release tablet, and oral solution. The
segment’s dominance can be attributed to the benefits offered by extended
release tablets such as reduced frequency of dosage over other dosage forms.
Request Customization on Metformin Hydrochloride API Market Report
–
https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=82470
North America to Lead Global Market; Asia Pacific
to Offer Significant Opportunities
In terms of region, the global metformin hydrochloride API market has
been segmented into North America, Europe, Latin America, Asia Pacific, and
Middle East & Africa. North America is projected to account for a leading
share of the global metformin hydrochloride API market during the forecast
period. High prevalence of diabetes and increase in geriatric population are
anticipated to drive the market in the region. According to the CDC,
nearly 34.2 million people have diabetes (10.5% of the
population) and around 88 million people above 18 years have
prediabetes (34.5% of the adult population) in the U.S. The market in Europe is
expected to expand at a high CAGR in the near future, owing to the presence of
local as well as global players and increase in the demand for metformin
hydrochloride API in the region.
The metformin hydrochloride API market in Asia Pacific is likely to grow
at a rapid pace in the near future. Rise in awareness and increase in
healthcare expenditure in the region are projected to propel the market in Asia
Pacific over the next few years.
Buy Metformin Hydrochloride API Market Report –
https://www.transparencymarketresearch.com/checkout.php?rep_id=82470<ype=S
Growth Strategies of Key Players
Key players operating in the global metformin hydrochloride API market
are Auro Laboratories Limited, Abhilasha Pharma Pvt. Ltd., Stanex Drugs &
Chemicals Pvt. Ltd., Fengchen Group Co., Ltd., NS Chemicals, Midas Pharma GmbH,
Harman Finochem Ltd., Aarti Drugs Ltd., Bayer AG, Ipca Laboratories Ltd.,
Panacea Biotech Ltd., Aristopharma Ltd., Sihuan Pharmaceutical Holdings Group
Ltd., Intas Pharmaceuticals Ltd., Bal Pharma Limited, Sohan Healthcare Pvt.
Ltd., JD Chem (I), Kothari Phytochemicals & Industries Ltd., Turtle Pharma
Private Limited, Shijiazhuang Polee Pharmaceutical Co., Ltd., Shouguang Fukang
Pharmaceutical Co., Ltd., USV Private Limited, Exemed Pharmaceuticals,
Farmhispania Group, Shandong Keyuan Pharmaceutical Co., Ltd. Merck KGaA, Taj
API, Vistin Pharma AS, and Wanbury Limited.
These companies adopt the strategy of capacity expansion in order to
expand market share. For instance, in November 2020, Aarti Drugs
Ltd. announced plans to expand the metformin hydrochloride API manufacturing
capacity to 3,000 TPM. The company will start the phase I expansion project to
2,000 TPM in FY20-21.
Global Metformin Hydrochloride API Market:
Segmentation
·
o
o
o
·
o
o
o
·
o
o
o
·
o
§
§
o
§
§
§
§
§
§
o
§
§
§
§
§
o
§
§
§
o
§
§
§
About Us
Transparency Market Research is a global market intelligence company
providing global business information reports and services. Our exclusive blend
of quantitative forecasting and trends analysis provides forward-looking
insight for thousands of decision makers. Our experienced team of analysts,
researchers, and consultants use proprietary data sources and various tools and
techniques to gather and analyze information.
Our data repository is continuously updated and revised by a team of
research experts, so that it always reflects the latest trends and information.
With a broad research and analysis capability, Transparency Market Research
employs rigorous primary and secondary research techniques in developing
distinctive data sets and research material for business reports.
Contact
Transparency Market Research,
90 Sate Street, Suite 700,
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
